Developing Story
GLP-1 Drug Mass Tort Litigation
A growing wave of lawsuits claims GLP-1 drugs like Ozempic cause serious harms such as blindness and pancreatitis, but the lack of reliable adverse-event data is complicating litigation and regulatory response.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
Ongoing lawsuits allege that GLP-1 drugs such as Ozempic can cause serious harm, including blindness (NAION) and pancreatitis, but scant adverse-event data makes it difficult to determine how often these harms occur, complicating both scientific and legal assessments (NPR, October 10). The litigation implicates the FDA's adverse-event reporting systems and drugmakers, and is likely to expand as GLP-1 use grows globally.